Nuvation Bio Inc. (NUVB)
$
1.66
-0.13 (-7.83%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on advancing therapeutic candidates in oncology, with its lead product candidate being NUV-422, a small molecule inhibitor that targets cyclin-dependent kinases (CDK) 2, 4, and 6. The company's commitment to oncology is further demonstrated through its development of NUV-868, a selective oral small molecule BET inhibitor that epigenetically influences the proteins responsible for tumor growth and differentiation. Additionally, they are working on NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase, which plays a critical role in DNA damage repair. Other noteworthy candidates in its pipeline include NUV-1182, an adenosine receptor inhibitor, and a drug-drug conjugate (DDC) platform that aims to combine inhibitors of poly ADP ribose polymerase (PARP) with anti-cancer agents to effectively target conditions like ER+ breast and ovarian cancer. The company reported depreciation and amortization expenses of $683,000.00 reflecting the wear and tear of its assets. The income before tax ratio stands at -72.14 illustrating the company’s pre-tax margin efficiency. Moreover, the gross profit ratio is 0.10 which indicates the effectiveness of its production and sales operations. Nuvation Bio's stock is identified with the symbol 'NUVB' in the marketplace, and it boasts an EBITDA of -$566,915,000.00 a critical measure of the company’s operational profitability. In terms of financial metrics, the stock is affordable at $1.75 making it suitable for budget-conscious investors. With a high average trading volume of 2,641,973.00 the stock indicates strong liquidity, reflecting an active interest from investors. With a market capitalization of $560,547,140.00 Nuvation Bio is categorized as a small-cap player, and it serves as a significant contributor in the Biotechnology industry, adding value to the overall market landscape. As part of the Healthcare sector, Nuvation Bio Inc. is dedicated to driving innovation and fostering growth within its field, positioning itself as a vital entity in the biopharmaceutical arena.
Is Nuvation Bio Inc. (NUVB) a good investment?
Investing in Nuvation Bio Inc. (NUVB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Nuvation Bio Inc. (NUVB)'s stock forecast?
Analysts predict Nuvation Bio Inc. stock to fluctuate between $1.64 (low) and $3.97 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Nuvation Bio Inc.'s market capitalization?
As of 2025-04-04, Nuvation Bio Inc.'s market cap is $560,547,140, based on 337,679,000 outstanding shares.
How does Nuvation Bio Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Nuvation Bio Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Nuvation Bio Inc. (NUVB) stock?
To buy Nuvation Bio Inc. (NUVB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for NUVB. Place an order (Market, Limit, etc.).
What is the best time to invest in Nuvation Bio Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Nuvation Bio Inc. perform in the last earnings report?
Revenue: $7,873,000 | EPS: -$2.11 | Growth: 502.86%.
Where can I find Nuvation Bio Inc.'s investor relations reports?
Visit https://www.nuvationbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Nuvation Bio Inc.?
You can explore historical data from here
What is the all-time high and low for Nuvation Bio Inc. stock?
All-time high: $15.23 (2021-05-26) | All-time low: $0.95 (2023-10-31).
What are the key trends affecting Nuvation Bio Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “Nuvation Bio had a transformative year in 2024, marked by significant milestones. We acquired AnHeart Therapeutics, reported positive pivotal data for taletrectinib, and submitted the NDA for taletrectinib, which was accep.
prnewswire.com
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access Program (EAP) for taletrectinib in the U.S. for the treatment of patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) when no comparable or satisfactory alternative therapy options are available. “This EAP reflects our unwavering dedication to patie.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT in San Francisco, California. A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuv.
prnewswire.com
SAN FRANCISCO and SUZHOU, China , Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The approval is based on positive results from the pivotal Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated the safety, tolerability and efficiency of taletrectinib in Chinese patients with advanced ROS1-positive NSCLC.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that the U.S. FDA has accepted the company's NDA for taletrectinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of advanced ROS1+ NSCLC (line agnostic). The U.S. FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2.
prnewswire.com
SAN FRANCISCO and SUZHOU, China , Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. DOVBLERON® marks the 13th addition to Innovent's commercial portfolio, representing an innovative precision therapy expected to benefit more lung cancer patients alongside our strong TKI franchise.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 9:10 a.m. ET. A live webcast of the fireside chat will be available on the.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an investigational next-generation ROS1 TKI. The findings will be highlighted in a poster presentation on September 14, 2024, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.
See all news
